In a setback to Actavis a federal court judge has issued a preliminary injunction that prevents the drug maker from pulling an older version of its Namenda medication for Alzheimers from pharmacy shelves The ruling comes three months after the New York state attorney general filed a lawsuitÂ alleging Actavis violated antitrust law by planning to prematurely end sales of the drug to force patients to switch to a newer version The lawsuit was filed shortly after Forest Laboratories which is now owned by Actavis halted sales of its twiceaday version of Namenda The patent on the older drug expires next year while the patent on the newer Namenda XR a onceaday pill doesnt expire until  This sort of switching is known in the pharmaceutical industry as product hopping